over different combinations of patient weight and surface area. RESULTS: Savings of €3,404 per course per patient were shown; potentially saving the Italian health care system €7.67 million per year. This assumes that of the 2,252 third-line patients, 57% receive panitumumab and 43% receive Active Supportive Care in Year 1 based on the prevalence of the wild-type K-RAS mutation, compared with 100% receiving cetuximab. CONCLUSIONS: Results indicate that substantial savings are associated with panitumumab therapy over cetuximab therapy at national and perpatient levels.
and therapy limiting toxicity which is classified into severity grades 1 to 3. METHODS: Between April 2006 and August 2007 an observational study was conducted in Bonn, Germany on two oncologic outpatient wards and three oncologic practices. Breast and colorectal cancer patients starting oral chemotherapy with capecitabine were included and followed for six months. They rated their HFS at the end of each capecitabine cycle. The HFS grades were transformed into utility weights obtained from an earlier study in our group. From the perspective of the German statutory health insurance the direct disease-related costs (outpatient costs for pharmacotherapy, oncologist visits, diagnostics and inpatient costs) were assessed in a microcosting approach and referred to 2008. RESULTS: Thirty patients (16 breast, 14 colorectal cancer) were included. Their mean HFS severity grade was 1.1 (SD 0.7, median 1.0, range 0 to 2.75) corresponding to a mean utility weight of 0.88 (SD 0.14, median 0.92, range 1.00 to 0.44). Seven patients showed a HFS grade 3 (utility weight: 0.34) at least in one capecitabine cycle. On average €18,305 (80.4% outpatient, 19.6% inpatient) were calculated per breast cancer patient and €25,863 (71.2% outpatient, 28.8% inpatient) per colorectal cancer patient. Concerning the outpatient treatment, costs for pharmacotherapy represented the highest matter of expense (96.0% breast, 95.0% colorectal cancer). CONCLU-SIONS: In most patients HFS occurred in moderate severity. Nevertheless, 7 patients experienced HFS grade 3 affecting quality of life. Strategies to prevent this toxicity need to be developed. Especially costs for pharmacotherapy represent a cost-driving factor in this patient group indicating a need for strategies to optimize cost structure while containing or improving quality of treatment. Panitumumab is the first fully human anti-EGFR monoclonal antibody to be approved as monotherapy for patients with wild type (wt) KRAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. This novel treatment approach is the beginning of a new era of personalised treatment whereby KRAS status is evaluated and only patients who are likely to respond (wt KRAS) receive treatment. The objective of this study was to evaluate the overall budget impact (BI) of the use of panitumumab versus testing KRAS and treating patients with wt KRAS in Greece. METHODS: To consider overall costs associated with panitumumab treatment versus testing KRAS status and treating only wt KRAS patients with panitumumab, a decision analytic model was developed to evaluate BI. Primary drug costs, concomitant medications, infusion costs, radiation therapy, clinic visits, and hospitalisations were included in treatment costs. An expert panel was employed to map mCRC patient flow as a local cancer registry was not available. In this analysis, cost calculations for the public and private sectors were conducted separately. RESULTS: Out of 470 potentially eligible patients for panitumumab monotherapy, the decision analytic model targets 268 (57%) patients with wt KRAS, according to indication. Potential total cost of receiving panitumumab without taking KRAS status into consideration was €8.4 million in the public sector, while total cost including KRAS testing to all patients but treating only the wt KRAS patients with panitumumab was €4.9 million, resulting in 41.7% savings. Total cost figures for the private sector were €8.7 million and €5 million respectively, resulting in 42.5% savings. CONCLUSIONS: By identifying the wt KRAS patients who are most likely to respond to treatment, panitumumab improves treatment outcomes and reduces unnecessary exposure to therapy, resulting in overall budget savings. Patient-level clinical benefits derived by panitumumab may lead to improvements in health outcomes and rational allocation of health care resources in Greece.
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PCN18 AN EVALUATION OF THE COST SAVINGS GENERATED WITH THE USE OF AN INTRA-OPERATIVE ASSAY FOR THE DETECTION OF METASTASES IN THE SENTINEL LYMPH NODES OF PATIENTS WITH BREAST CANCER
Durbecq V,Veys I, Majjaj S, Schobbens JC, Noterman D, Filippov V, Sirtaine N, Bourgeois P, Nogaret J, Larsimont D Institut Jules Bordet, Bruxelles, Belgium OBJECTIVES: A molecular assay (GeneSearch™ Breast Lymph Node (BLN) Assay, Veridex, LLC), CE marked and approved by the FDA, has been in clinical use at our institution for over 18 months to intra-operatively detect metastases 3 0.2 mm in the sentinel lymph nodes (SLNs) of breast cancer patients. After a small validation study (N = 78, sensitivity = 92.3%, specificity = 96.9%) the assay was adopted as the only intra-operative SLN test used at the Institut Jules Bordet. This is the first evaluation of the cost savings generated by the use of this BLN assay. METHODS: An economic evaluation was conducted in the first 300 patients in whom this BLN assay was used intra-operatively. The BLN assay results are used to make intra-operative decisions for axillary lymph node dissections (ALND) during the same surgery. We assessed the pathology, surgery & anesthesia, pharmacy, post-hospitalization, general, and total costs associated with patients having either: Surgery A = a lumpectomy + SLN + secondary ALND versus having: Surgery B = a lumpectomy + BLN + ALND. RESULTS: The total costs per patient for Surgery A was €3120, while for Surgery B it was €2210. Therefore, a difference of €910, were saved per patient when using the BLN assay, which represents a 29% cost savings. Since 58 patients avoided having a second surgery, the total cost savings accrued by the institution for the Belgian social security system as a result of using the BLN assay in this first cohort of 300 patients, was €52,780. CONCLUSIONS: The BLN assay was proved to be beneficial not only for our patients by reducing the need of second surgeries, it has also been demonstrated to be cost saving for the Belgian social security system. Its use at the Institut Jules Bordet in the first cohort of 300 patients has resulted in a cost savings of €52,780. [1] which demonstrated correlation between response rates to chemotherapy and resection rates. Base case resection rates (active/comparator) of 22%/12% (FOLFIRI) and 15%/7% (FOLFOX) were assumed using this correlation. The long-term benefits of surgery were estimated from Adam et al [2] . Treatment in specialised centres may lead to vial sharing and higher resection rates (55%/35% and 42%/26% respectively), these assumptions are tested in sensitivity analysis. The 1 st line utility value (0.77) in the model was derived from EQ5D data collected in the FOLFIRI trial. RESULTS: In the basecase the addition of cetuximab to FOLFIRI/FOLFOX resulted in: incremental life years gained of 0.358 and 0.413; additional QALYs of 0.281 and 0.320; incremental cost effectiveness ratios (ICERs) of £69,287 and £63,245 per QALY and ICERs in specialised centres of £34,646 and £40,529. The ICER is mainly driven by the number of patients becoming resectable the acquisition cost of cetuximab, and parameterisation of the progression-free survival curves. CONCLUSIONS: The analysis demonstrates the role of cetuximab in enabling curative surgery which drives the cost-effectiveness. When assessing a highly selected group of patients within a subset with wild-type KRAS, the ICERs are close to UK willingness to pay acceptance thresh- To evaluate the cost-effectiveness of standard chemotherapy plus adjuvant trastuzumab treatment for one year compared to standard chemotherapy in patients with early breast cancer in Saudi Arabia. METHODS: A Markov model was adapted to estimate the costs and clinical outcomes (qualityadjusted life-years (QALYs) and life expectancy) associated with the progression of early breast cancer over patients' lifetimes. Patients transitioned through five health states according to probabilities reflecting the rates of disease progression observed in the HERA (HERceptin Adjuvant) trial. Total health care resource costs and utilization were estimated for each health state using values derived from a Saudi Arabian-specific survey. The analysis was done from the perspectives of the health care provider and society. The mean starting treatment age was assumed to be 30 years old, reflecting local demographics. Costs and outcomes were discounted at 3.5% per annum. Sensitivity analyses were performed. RESULTS: One-year adjuvant treatment with trastuzumab was estimated to increase life expectancy by 2.4 (4.9 undiscounted) years and quality-adjusted life years by 2.2 (4.3 undiscounted) QALYs, compared to standard chemotherapy. Over a patient's lifetime, total direct medical costs, including indirect costs (attributed to travel and time off work for patients and care-givers), were projected to increase by approximately SR48,452 (US$12,903) compared to chemotherapy alone. Treatment with trastuzumab was estimated to partially offset mean event and state costs compared to chemotherapy
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